In nephrotic syndrome, aberrant glomerular filtration of plasminogen and conversion to active 31 plasmin in pre-urine is thought to activate proteolytically ENaC and contribute to sodium 32 retention and edema. The ENaC blocker amiloride is an off-target inhibitor of urokinase-type 33 plasminogen activator (uPA) in vitro. It was hypothesized that uPA is abnormally filtered to pre-34 urine and is inhibited in urine by amiloride in nephrotic syndrome. This was tested by 35 determination of Na + -balance, uPA protein and activity and amiloride concentration in urine 36 from rats with puromycin aminonucleoside (PAN) induced nephrotic syndrome. Urine samples 37 from 6 adult and 18 pediatric patients with nephrotic syndrome were analyzed for uPA activity 38 and protein. PAN-treatment induced significant proteinuria in rats which coincided with 39 increased urine uPA protein and activity, increased urine protease activity and total 40 plasminogen/plasmin concentration and Na + retention. Amiloride (2mg/kg/24h) concentration in 41 urine was in the range 10-20 µmol/L and reduced significantly urine uPA activity, plasminogen 42 activation, protease activity and sodium retention in PAN rats, while proteinuria was not altered. 43
Introduction 50
Edema associated with nephrotic syndrome (NS) is caused not only by altered Starling forces, 51 but with a significant contribution from a primary impairment of renal NaCl excretion: In the 52 unilateral nephrotic rat model (20) , sodium retention is associated with the nephrotic kidney 53 injection rats were shifted to milli-Q (MQ) water and a gel formula of rat chow by mixing agar 101 (ash: 2-4.5%, Sigma-Aldrich, St. Louis, MO, USA) and milli-Q water with granulated standard 102 rat chow to avoid contamination of urine and feces with chow. Recipe proportions for, 103
Agar:Chow:MQ water was 1:30:50, respectively. MQ water was preheated to 60-65˚C before 104 chow and agar were added. Two days prior to the PAN inj., rats were separated and placed 105 individually in metabolic cages. Control 24 hour urine collection (day -1) was collected after a 106 24 hour adjustment period in the metabolic cage. PAN (Sigma-Aldrich) 15 mg / 1 ml isotonic 107 NaCl / 100 g BW was administered by intraperitoneal injection at day 0. Rats were kept with 108 free access to gel-chow and MQ water throughout the experiment and daily intake was recorded. 109
Amiloride (2 mg / kg) was dissolved in an isotonic NaCl solution and administered 110 subcutaneously from day 4 at 9 AM. Control and PAN (vehicle/control) groups were injected 111 with vehicle isotonic NaCl in equivalent amounts. The 24 hour urine samples were aliquoted and 112 kept at -20˚C. Twenty seven rats were included in the study. Fifteen rats had intraperitoneal PAN 113 injection but 3 out of 15 rats did not develop adequate proteinuria (defined as: urine protein 114 excretion > 0.1 g / 24 h /100 g BW on day 4). These rats were excluded from the study. Of the 12 115 rats that developed proteinuria, 6 rats were treated with amiloride (2 mg / kg BW) administered 116 s.c. once daily from day 4 (PAN + Amiloride group) and 6 rats received vehicle-amiloride (PAN 117 group). Of the 12 vehicle-PAN injected rats, 6 rats were subcutaneously injected with vehicle-118 amiloride (Control group) and 6 rats were injected with amiloride (Amiloride group). 119 Urine Analyses. Urine samples were centrifuged at 16.000 ×g for 30 seconds and experiments 120 were done using the supernatant. In general, human spot urine samples were calibrated for 121 creatinine concentration in e.g. western blotting, whereas rat samples drawn from 24h-urine 122 collections were not normalized. Plasmin/plasminogen: 3 μL of crude urine was loaded. After blotting, the membrane was 135 subsequently blocked in TBST with 5% skimmed milk and hereafter subjected to primary anti-136 plasminogen antibody 1:5000 (ab6189, abcam®, Cambridge, UK) followed by secondary 137
Polyclonal Rabbit Anti-Goat Immunoglobulins/HRP (Dako, Glostrup, DK). uPA: Human urine 138 (5g/L creatinine) or 10 μL rat urine was loaded. After blotting, the membrane was blocked in 139 TBST with 5% skimmed milk and hereafter subjected to primary Anti-uPA antibody Santa Cruz, Heidelberg, Germany) was purchased from Sigma-Aldrich, Steinheim, Germany. Stock solutions of 1 mg/mL were 157 prepared in Milli-Q water. Working solutions were also prepared in Milli-Q water. All solutions 158 were prepared in amber glass vials to protect from daylight. Acetonitrile (CHROMASOLV for 159 liquid chromatography) was purchased from Sigma-Aldrich, Steinheim, Germany. Ammonium 160 acetate was purchased from Fluka Chemie GmbH, Buchs, Schweiz. HPLC conditions: The 161
High-Performance Liquid Chromatography system was a LaChrom 7000 serie system and 162 consisted of an L-7100 pump, an L-7250 autosampler, an L-7300 column oven, an L-7400 UV-163 detector and a D-7000 interface module (Merck-Hitachi, Japan). The analytical column was a 164 Luna HILIC (3 μm) 150 x 4.6 mm column equipped with a HILIC SecurityGuard precolumn 165 (Phenomenex, Torrance, CA). The mobile phase consisted of acetonitrile: 100 mM ammonium 166 acetate, pH 5.8 (93:7) and was used at a flow rate of 1.5 mL/min. Amiloride was detected at a 167 UV-wavelength of 362 nm and eluted at 6.2 min; whereas metformin was detected at 234 nm 168 and eluted at 7.8 min. The total analysis time was 10 minutes. Sample preparation: A volume of 169 100 μL of the urine sample was transferred to a 9 mL conical glass test tube. Aliquots of 30 μL 170 50 μg/mL metformin (internal standard); 30 μL 5M NaOH and 2125 μL acetonitrile were also 171 added, and the test tube was whirly mixed for 30 sec. The sample was then centrifuged at 3000 g 172 in 2 minutes, and 150 μL was transferred to a 0.3 mL HPLC vial. The samples were protected 173 from daylight during sample preparation. A sample volume of 50 μL was injected onto the 174 column. 175
Calibration curves with 5 concentrations in a range from 2.5 -20 μg/mL spiked in blank urine 176 was produced each day of analysis. Quality control samples were also included in each series. 177
The interday variability was < 2% and the mean precision was 98 %. The limit of quantification 178 with the applied method was 0.15 ug/mL. 179
Statistic evaluation Data from children urine sample analysis was evaluated by paired Student´s t 180 test. Two-way analysis of variance (2 way-ANOVA) was applied when comparing the four 181 groups with 2 categorical variables (w/wo PAN; w/wo amiloride), followed by Bonferroni´s 182
Multiple Comparison post hoc test to determine significant differences between groups. For all 183 data, P values below 0.05 were considered significant. Statistical analyses were performed using 184
Prism 5 software (GraphPad). 185 186 187
Results

188
Nephrotic syndrome is associated with changes of uPA in urine 189
On the first days after treatment, puromycin aminonucleoside (PAN) administration led to 190 progressive and significant proteinuria in the rats that stabilized at day 4 post injection ( Figure  191 1A). Amiloride treatment did not alter 24h urine protein excretion in control rats or in treated rats ( Figure 1A To examine human correlate, 18 paired urine samples from acute, idiopathic, childhood 220 nephrotic syndrome patients were compared by ELISA in the acute and remission phases. Urine 221 uPA/creatinine concentration ratio was significantly decreased at remission compared to acute 222 phase ( Figure 3A) . Separation of the urine samples under denaturing conditions followed by 223 immunoblotting for uPA showed in 15 samples a significant presence of a protein at 33 kDa 224 compatible with uPA in the acute phase while in the remission phase the signal was decreased in 225 9 samples (data not shown). Urine uPA activity ( Figure 3B ) and uPA protein concentration by 226 ELISA ( Figure 3C ) correlated directly with 24h urine protein excretion in 6 adult nephrotic 227 syndrome patients. Immunoblotting of urine samples from the adult nephrotic syndrome patients 228 and 3 healthy controls displayed significant uPA immunoreactive protein ( Figure 3D) . 229
230
Effect of amiloride on Na + and water excretion in PAN nephrotic rats 231
Urine sodium excretion decreased significantly within the first 24 hours after PAN which 232 persisted throughout the study compared to control rats ( Figure 4A ). The initial decline in 233 sodium excretion is caused predominantly by a decreased intake as shown in detail before (35) 234 and as seen by the negative balance in panel 4C. Administration of amiloride at day 4-6 post-235 PAN induced a significant increase in sodium excretion compared to PAN-vehicle ( Figure 4A) . 236
Control rats increased sodium excretion transiently in the first 24h after amiloride ( Figure 4A) . 237
At day 6, the PAN-amiloride rats had sodium excretion similar to control rats. PAN-treatment 238 resulted in accumulation of free ascites fluid in the abdominal cavity that was significantly 239 diminished by amiloride treatment through days 4-6 post PAN and measured at day 7 at 240 termination ( Figure 4B ). Since food intake varied just after PAN treatment as shown before (35), 241 urine sodium balance was calculated and PAN rats accumulated sodium coincident with 242 proteinuria at day 3-4 post-PAN compared to control rats ( Figure 4C ). Amiloride abolished the 243 difference ( Figure 4C ). No significant difference was observed in the intake of food or water 244 between PAN + amiloride vs. PAN or control vs. amiloride, respectively. 245
246
Discussion 247
The present study shows in patients and in experimental animals that nephrotic syndrome is 248 associated with significantly increased, reversible, urinary excretion of urokinase-type 249 plasminogen activator (uPA) and that amiloride, a K + -sparing diuretic, significantly reduces 250 urine uPA activity; plasminogen-to-plasmin activation in urine; urinary protease activity and 251 renal sodium retention and ascites formation in nephrotic rats. It is concluded that ENaC is 252 necessary for Na + retention and edema formation in nephrotic syndrome in rats and that urine 253 uPA is a relevant target for amiloride. Human urine samples corroborated that increased urine 254 uPA level is associated with nephrosis. 255
The significant natriuretic effect of amiloride in PAN-induced nephrotic syndrome in rats is well 256 established (15, 35). A single study in pediatric patients confirms a significant natriuretic action 257 at least equivalent to furosemide (14). The effect has mainly been attributed to the direct 258 blockade of ENaC (32). The present data suggest a potential contribution of amiloride to 259 natriuresis also by attenuation of plasminogen to plasmin activation ( Figure 5 ). The present data 260 do not allow discrimination between the direct ENaC inhibition and the attenuated activity of 261 uPA/plasmin in the natriuretic action of amiloride. The data support that amiloride inhibits urine 262 uPA activity by competitive antagonism since overall proteinuria and uPA protein abundance 263
were not diminished. Binding of pro-uPA to the uPA receptor (uPAR) leads to activation of uPA 264 and amiloride is able to reduce LPS-induced uPAR expression in podocytes and cancer cells (43, 265 45). It can therefore not be excluded that reduced podocyte uPAR expression by amiloride has 266 contributed to decreased urine uPA activity. In vitro, amiloride inhibits uPA with a K i of 7 267 µmol/L (40) and such concentrations were surpassed in the present rat urine samples with a daily 268 dosage of 2mg/kg amiloride. This concentration range may be reached also in human urine (34). 269
Because uPA has been shown in vitro also to activate ENaC directly (11, 21), inhibition of uPA 270 by amiloride may thus attenuate proteolytic activation of ENaC directly and indirectly through 271 diminished plasmin (10, 15, 19, 35) . In high concentrations, plasmin directly cleaves γ-ENaC, 272 while at lower concentrations, it depends on a cascade with prostasin as the final mediator (29, 273 36). There may be other therapeutic benefits from inhibition of aberrant plasmin activation by 274 amiloride in urine such as prevention of the negative modulation of TRPV5 by plasmin (37). 275
Moreover, uPA/uPAR activity has been associated with glomerular affection in diabetic 276 nephropathy (22, 27) . As to the origin of urine uPA, it circulates freely in plasma and is 277 synthesized along the tubular epithelium (31, 42) where immunoreactive uPA is associated with 278 the collecting duct (35). The abrupt increase in urine uPA with induction of glomerular damage 279 in rats and the decline in children with nephrosis in remission indicate aberrant filtration as a 280 significant contributor but clearly with a baseline level visible in normal control urine. In 281 nephrotic syndrome, plasma plasminogen decreases (2) while it increases in urine where it 282 correlates with albumin and since it is not produced by the epithelium, it derives predominantly 283 from aberrant filtration. The inactive 55 kDa single-chain uPA precursor is activated by 284 proteolytical cleavage by various proteases including plasmin which generates a high molecular 285 weight (HMW) active two-chain enzyme held together by a single disulfide-bridge (18, 28). The 286 denaturing western blotting revealed a product in urine compatible with the heavy chain ( Figures  287   1 and 3) . The precursor and active HMW-uPA bind with high affinity to the uPA receptor uPAR 288 (12). The present data suggest that no inactive single chain is present in urine. This could be due 289 to an amplifying mutual activation between uPA and plasminogen/plasmin. The significant 290 positive correlation between urine uPA and protein in adult nephrosis patients further supports 291 that pathophysiological filtration of uPA from plasma across an injured glomerular barrier may 292 account for the increase in urine uPA. A similar observation on plasma uPA has been previously 293 observed (3). The combined urinary loss of fibrinolytic plasminogen and uPA may be causally 294 related to the hypercoagulable, prothrombotic state associated with nephrotic syndrome (23). 295
Conclusion 296
Urokinase-type plasminogen activator is aberrantly co-filtrated with plasminogen through the 297 injured glomerular filtration barrier in human and experimental nephrotic syndrome where it 298 promotes activation of plasminogen to plasmin in pre-urine. Amiloride attenuates urine uPA 299 activity which may by an additional beneficial therapeutic target to counter ENaC-mediated 300 sodium retention and edema formation. 301 302 303
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Legends to figures 317
Figure 1 318
The figure shows the effect of puromycin aminonucleoside (PAN) at day 0 with and without 319 amiloride treatment from day 4 on urinary protein excretion and uPA protein abundance in urine 320 from rats. A Four days after PAN injection, protein excretion was significantly elevated in PAN 321
injected rats compared to non-PAN inj. control rats whereas no significant difference was 322 observed between PAN and PAN+amiloride treated rats (two way ANOVA p<0.0001, n=6-8). B 323 western immunoblotting for uPA protein in urine showed that uPA was present at low levels in 324 control-vehicle rats and prior to PAN injection (day -1). There were increased urine uPA levels 325
at day 4 and 6 after PAN treatment (n=6). C uPA protein level in urine was compared between 326 groups at day 4 with significant proteinuria. Level of uPA was significantly increased in PAN 327 rats compared to vehicle-treated rats. Amiloride treatment did not affect uPA protein abundance 328 in vehicle or PAN rats (n=6). Data were evaluated by one way ANOVA followed by Bonferroni 329 Post Hoc test. * Statistically significant difference between groups at P<0.05. Rats from the group of PAN + amiloride displayed significantly less accumulation of ascites 371 fluid in the abdomen compared to rats in the group of PAN+vehicle (2-way ANOVA, *p<0.05 372 and ***p<0.001, Post-hoc test was Bonferroni's Multiple Comparison Test) . 373 C The curve shows sodium balance calculated by subtracting 24h excreted urinary sodium from 374 daily sodium intake through chow and injection. Feces sodium excretion was not measured. In 375 the acute phase after PAN, there is net loss of Na+ through urine. As proteinuria develops, and 376 despite lower intake of chow, PAN rats accumulate more sodium compared to control rats from 377 day 3 coinciding with the development of proteinuria. *: p<0.05, two way ANOVA followed by 378 post-hoc Bonferroni multiple comparison test. 379 380
Figure 5 381
Effect of amiloride on uPA and ENaC in nephrotic syndrome. uPA is aberrantly co-filtered with 382 plasminogen through the injured glomerular filtration barrier during nephrotic syndrome and is 383 also thought to be secreted by the tubular epithelium. In the pre-urine, uPA activates 384 plasminogen to plasmin. Plasmin may also activate pro-uPA. Plasmin activates the gamma 385 subunit of ENaC through proteolytical cleavage leading to sodium retention. Amiloride 386
attenuates not only urine uPA activity but also has a direct inhibitory effect on ENaC. 
